XML 52 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:      
Net loss $ (28,491,153) $ (21,328,536) $ (25,243,551)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 991,721 1,207,911 1,520,772
Stock-based compensation for employees and external services 2,878,134 3,260,937 3,929,634
Loss (gain) on disposal of fixed assets 20,883 32,145 (10,462)
Write-down of fixed assets 27,500   62,807
Loss on disposal of intangible assets     67,151
Impairment of intangible asset   654,961  
Gain from settlement agreement, net     (226,580)
Gain on sale of marketable securities   (83,750)  
Change in fair value of warrant liability 5,944,571 (6,612,092) (3,005,040)
Changes in operating assets and liabilities:      
Other receivables 39,825 (78,503) 550,282
Trade receivables (50,451) 67,974 (39,146)
Prepaid and other current assets 22,232 495,662 (437,110)
Other assets 89,790 76,187 601,532
Accounts payable and accrued expenses (409,333) 130,766 (808,722)
Accrued wind-down expenses (1,032,024) (1,165,585) (1,202,733)
Deferred revenue 13,389 (18,903) (79,211)
Deferred rent 85,572 1,302,543 (129,764)
Deposits and other long-term liabilities     (69,772)
Net cash used in operating activities (19,869,344) (22,058,283) (24,519,913)
Cash flows from investing activities:      
Purchases of marketable debt securities (16,380,748) (10,188,285)  
Sales or maturities of marketable debt securities 5,762,000 6,905,000  
Proceeds from sales of marketable equity securities   158,206  
Purchases of property, plant and equipment (73,083) (296,933) (923,964)
Net cash used in investing activities (10,691,831) (3,422,012) (923,964)
Cash flows from financing activities:      
Proceeds from issuance of common stock, net 19,747,550 19,774,820 7,279,234
Proceeds from the exercise of stock options 3,629 2,386 19,802
Payments related to net share issuance of stock based awards (59,090) (403,625) (483,406)
Proceeds from the exercise of warrants 6,256,438    
Proceeds (repayments) of capital lease obligations (20,167) (67,847) (68,000)
Repayments of bonds payable (191,250) (176,250) (161,250)
Net cash provided by financing activities 25,737,110 19,129,484 6,586,380
Decrease in cash and cash equivalents (4,824,065) (6,350,811) (18,857,497)
Cash and cash equivalents at beginning of year 13,311,261 19,707,821 38,617,977
Effects of foreign currency rate changes on cash (15,921) (45,749) (52,659)
Cash and cash equivalents at end of the year 8,471,275 13,311,261 19,707,821
Supplemental disclosure of cash flow information:      
Interest paid 50,193 71,363 93,382
Supplemental schedule of non-cash investing and financing activities:      
Stock issued for an option agreement (1) 50,000 [1]    
Equipment acquired under a capital lease (2) 21,721 [2]    
Stock retired from settlement agreement (3)     $ 241,150 [3]
[1] In September 2012, we issued 24,753 shares of restricted common stock under the terms of an agreement with a developer of biological materials in return for certain product rights including an exclusive right of first offer to commercialize the developer's products as may be developed on or before April 18, 2017.
[2] Represents the present value of future minimum capital lease payments for equipment leased in the third quarter of 2012.
[3] On April 1, 2009, we acquired the operations of Stem Cell Sciences Plc (SCS), which changed its name to Asset Realization Company Limited. Pursuant to the acquisition agreement, 53,000 shares were placed into an escrow for a twelve month period to satisfy any indemnification obligations owed to us by SCS. On August 19, 2010, we entered into a settlement agreement with SCS in which the parties agreed to the release of half the escrowed shares to SCS and half to us in full satisfaction of our claims for indemnification, and both parties waived all other claims, known and unknown, against the other. The 26,500 shares returned to us are being treated as retired and no longer outstanding. We have recorded approximately $227,000 as other income, which was the value of these shares based on the closing price of $9.10 per share on August 19, 2010, and net of amounts already accrued for potential claims against the escrowed shares.